[4][5][6] Abexinostat exerts its effect as a pan-histone deacetylase inhibitor[7][8] and inhibits RAD51, which is involved in repairing DNA double strand breaks.

[9] Abexinostat has been granted a fast track designation by the FDA for the treatment of patients with relapsed or refractory follicular lymphoma in the fourth-line setting.

This designation is significant as it aims to expedite the development and review of drugs intended to treat serious conditions and fill an unmet medical need.

The FORERUNNER conducted a study, a potentially pivotal phase II trial of abexinostat monotherapy in patients with relapsed/refractory follicular lymphoma, in the United States and Europe.

[10] Abexinostat has been characterized by its unique pharmacokinetic profile and oral dosing schedule, allowing for continuous exposure at concentrations required for efficient tumor cell killing.